The last remaining work of my PhD got published today 🥳
In this communication, we highlight the possible effects of long term sample storage on blood DNA methylation patterns. 🧬👩🏻🔬
@VanmierloTim@rice_science
https://t.co/usaDEuuE9u
Let this be an encouragement to fellow scientists struggling with obtaining the oh so desired significant and positive data. Data from any experiment deserves to be shared with the field 📚 ☀
New paper alert 🚨🚨
Check out our most recently published paper, by Lieve van Veggel, about the ongoing search for an EAAT activator.
@VanmierloTim@BIOMED_UHasselt @MaastrichtU @UniLeidenNews
https://t.co/NkV2Coj6Bh
Excited to present my poster today at the Glia conference in Berlin about our latest publication on DNA methylation and myelination in Multiple sclerosis. 🧠🧬 #glia2023#myelin@VanmierloTim@rice_science
Starting off the week on a good note!! 🥳
Check out another one of our newly published papers about how PDE4D isoforms affect neurite elongation, specifically in the context of Alzheimer's disease.
@VanmierloTim @MaastrichtU @BIOMED_UHasselt
https://t.co/cHFkV4B6eD
In our team, we have PhD defenses followed by paper publications!🥳
Check out our most recent paper in Acta Neuropathologica about the epigenomic and transcriptomic profile of MS lesions.
Congrats to everyone involved! 👏🏼👏🏼
@TianeAssia@BIOMED_UHasselt @MaastrichtU
Interested in how methylation regulates myelination in multiple sclerosis lesions? Read our latest paper in Acta Neuropathologica by Assia Tiane et al.
https://t.co/9jIOrajb4X
Hora est! 👩🏻🎓
Yesterday marked a milestone in my academic career. I successfully defended my thesis “Relieving the epigenetic blockade in progressive MS - making remyelination accessible again”, the result of my joint PhD between @uhasselt and @MaastrichtU.
A big congratulations to our Dr. Tiane for defending her thesis titled:
"Relieving the epigenetic blockade in progressive MS - making remyelination accesible again"
Proud of you for this major achievement! 👏🏼👏🏼👏🏼
@BIOMED_UHasselt @MaastrichtU
Congratulations to Dr. Melissa Schepers for defending her PhD thesis on PDE4 inhibition: a novel approach to treat demyelinating disorders. 🥂
Proud of you for this major achievement👏🏼
Congratulations 🥳
@MaastrichtU @BIOMED_UHasselt@uhasselt
Our team is having a great start to 2023! Check out a preprint of our latest paper on the epigenomic and transcriptomic profile of chronically demyelinated MS lesions 🧠. Well done @TianeAssia!🥳
@biorxivpreprint@BIOMED_UHasselt
Excited to share our latest data on the epigenomic and transcriptomic profile of chronically demyelinated MS lesions, recently published as a preprint on bioRxiv. 🧬
@rice_science@VanmierloTim@BIOMED_UHasselt
https://t.co/ERiiLUvrE3
Excited to share our latest data on the epigenomic and transcriptomic profile of chronically demyelinated MS lesions, recently published as a preprint on bioRxiv. 🧬
@rice_science@VanmierloTim@BIOMED_UHasselt
https://t.co/ERiiLUvrE3
Check out our most recent paper about PDE4 subtype inhibition and its implications for multiple sclerosis.
Congratulations to our Melissa Schepers, well done!!
At the very end of this year, I am excited to share our latest paper @rice_science in Brain, Behavior, and Immunity by Melissa Schepers.
AddThis | Home https://t.co/Rb0HEVl9sl
At the very end of this year, I am excited to share our latest paper @rice_science in Brain, Behavior, and Immunity by Melissa Schepers.
AddThis | Home https://t.co/Rb0HEVl9sl
Do not forget to sign up for out #symposium (30.11.2022) and being part of setting up a new #network in #Belgium to bring researchers interested in blood brain barriers together.
#BBBelgium https://t.co/ijfKOrAioj
Catherine Lubetzki at #ECTRIMS2022 : Remyelination is currently THE major challenge in multiple sclerosis. Luckily we have quite some expertise about this at @BIOMED_UHasselt 😉